⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27814598 | 1.00 | — | — | |
| SCHEMBL2971141 | 0.93 | CHRM5 (0.38) | — | |
| SCHEMBL2883956 | 0.85 | — | — | |
| SCHEMBL1428205 | 0.85 | — | — | |
| SCHEMBL2978622 | 0.84 | NCF1 (0.48) | — | |
| SCHEMBL1099314 | 0.82 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL5956249 | 0.82 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL1988414 | 0.81 | — | — | |
| SCHEMBL1098647 | 0.79 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL12385889 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-08-02 | — | — | US | claimed |
| CN-107660205-B | Heterocyclic compounds as LSD1 inhibitors | 因赛特公司 | 2021-08-27 | — | — | CN | claimed |
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION | 2020-12-17 | — | — | US | claimed |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | claimed |
| US-10640503-B2 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-05-05 | — | — | US | claimed |
| EP-3626720-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | Incyte Corporation (US) | 2020-03-25 | — | — | EP | claimed |
| US-10556908-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-02-11 | — | — | US | claimed |
| EP-3277689-B1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORP (US) | 2019-09-04 | — | — | EP | claimed |
| US-20190106426-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-04-11 | — | — | US | claimed |
| US-20190055250-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-02-21 | — | — | US | claimed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | claimed |
| WO-2001066099-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | claimed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | claimed |
| EP-1117653-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2001-07-25 | — | — | EP | claimed |
| EP-1102743-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | claimed |
| WO-2001027089-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-04-19 | — | — | WO | claimed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | claimed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | claimed |
| WO-2000020402-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | claimed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | claimed |